Primary Aldosteronism Clinical Trial
— PAGODEOfficial title:
Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment
Verified date | April 2016 |
Source | Radboud University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Netherlands: Medical Ethics Review Committee (METC) |
Study type | Observational |
Primary aldosteronism (PA) is the most frequent form of secondary hypertension. It is caused
by autonomous secretion of aldosterone, encompassing a group of disorders which is for 99%
predominated by unilateral aldosterone-producing adenoma (APA) and bilateral adrenal
hyperplasia (BAH). Diagnosis of PA is relevant for two reasons:
1. independent of the level of blood pressure, hypertension due to autonomous aldosterone
secretion causes more cardiovascular damage than essential hypertension;
2. PA requires specific treatment: adrenalectomy in case of APA and mineralocorticoid
receptor antagonists (MRA) in case of BAH.
Although previously presumed a rare condition (prevalence <1%), PA is now estimated to
affect 6 to 20% of the hypertensive population. Given this high prevalence of PA, as well as
the amount of cardiovascular damage and the available specific treatment, the question is
raised whether screening of PA should be introduced in Dutch general practice. To answer
this important question, several issues with regard to PA need to be elucidated:
1. International studies report a prevalence of PA in general practice of 6-13%.
Prevalence in the Dutch population is still unknown;
2. Because of underdiagnosis of PA and long delay in diagnosis of PA after recognition of
hypertension (mean eight years), data on characteristics of early diagnosed PA are
lacking. Proof of early cardiovascular damage would strengthen the case of screening
for PA and needs to be studied;
3. Consequently, the diagnostic delay has lead to lack of data on optimal treatment in
early PA. In the current guideline (NHG-guideline 'Cardiovascular risk management') a
regimen of antihypertensive drugs is advised, and only if hypertension is refractory
for >6 months patients are referred. It is unknown if hypertension is resistant to
therapy in the initial phase of PA. If not, this would also argue for early biochemical
screening for PA, because even if blood pressure is controlled, the detrimental effect
of aldosterone itself will go on unopposed. It is therefore required to study the
response to antihypertensive drugs (not MRA) in these patients.
Status | Completed |
Enrollment | 700 |
Est. completion date | February 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Part 1: 1. Newly diagnosed hypertensive patients (according to the NHG-guideline 'Cardiovascular risk management'); 2. 18 years or older; 3. No use of antihypertensive medication. Part 2: 1. Patients with increased aldosterone/renin ratio; 2. Positive sodium loading test; 3. Written informed consent. Part 2 + 3: 1. Patients with normal aldosterone/renin ratio; 2. Normal ARR; 3. Written informed consent. Part 3: 1. Patients with increased aldosterone/renin ratio; 2. Positive sodium loading test; 3. Normokalemic; 4. Written informed consent. Exclusion Criteria: 1. Use of antihypertensive medication; 2. Heart failure class II, III or IV (according to the New York Heart Association); 3. Pregnancy or breastfeeding. |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Netherlands | Radboud university medical center | Nijmegen | Gelderland |
Lead Sponsor | Collaborator |
---|---|
Radboud University |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | PAGODE part 2: organ damage | To observe differences between newly diagnosed hypertensive patients with versus without primary aldosteronism in: Serum sodium; Serum glucose; Diastolic blood pressure. |
4 weeks | No |
Other | PAGODE part 3: blood pressure regulation | To observe differences between newly diagnosed hypertensive patients with versus without primary aldosteronism in: Reduction in 24 hour ABPM using conventional antihypertensive medication; Reduction in 24 hour ABPM using mineralocorticoid receptor antagonists. |
4 months | No |
Primary | PAGODE part 1: prevalence | Prevalence of primary aldosteronism in newly diagnosed hypertensive patients in Dutch general practice. | 4 months | No |
Primary | PAGODE part 2: organ damage | Difference in cardiorenovascular damage in patients with versus without primary aldosteronism, based on a composite of the following parameters: Left ventricular mass index in g/m2; Intima-media thickness of carotid artery in mm; Pulse wave velocity in m/s; Central aortic blood pressure in mmHg; Flow-mediated dilation in %; Albuminuria in mg albumin per mmol creatinin. |
4 weeks | No |
Primary | PAGODE part 3: blood pressure regulation | Difference in reduction of daytime systolic ambulatory blood pressure measurement (ABPM) in patients with normokalemic primary aldosteronism versus patients with essential hypertension in a standardized treatment regimen during conventional antihypertensive therapy. | 4 months | No |
Secondary | PAGODE part 2: organ damage | To observe differences between newly diagnosed hypertensive patients with versus without primary aldosteronism in: Serum potassium; Low density lipoprotein; Total cholesterol to high density lipoprotein ratio. |
4 weeks | No |
Secondary | PAGODE part 3: blood pressure regulation | To observe differences between newly diagnosed hypertensive patients with versus without primary aldosteronism in: Reduction of daytime systolic ABPM in patients with primary aldosteronism versus patients with essential hypertension in a standardized treatment regimen during spironolactone (or eplerenone); Serum potassium response using conventional antihypertensive medication; Adverse effects using conventional antihypertensive medication; Serum potassium response using spironolactone (or eplerenone); Adverse effects using spironolactone (or eplerenone). |
4 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02885662 -
Study of CS-3150 in Patients With Primary Aldosteronism
|
N/A | |
Withdrawn |
NCT02096939 -
Microvascular Function in Primary Aldosteronism
|
N/A | |
Recruiting |
NCT06228677 -
Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
|
||
Recruiting |
NCT06047912 -
Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone
|
||
Recruiting |
NCT04991961 -
Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Screening for Primary Aldosteronism
|
||
Recruiting |
NCT05405101 -
Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA
|
N/A | |
Recruiting |
NCT05501080 -
The Effect of SAAE on Ventricular Remodeling in PA Patients
|
N/A | |
Recruiting |
NCT05973604 -
Prevalence of Primary Aldosteronism in Atrial Fibrillation
|
||
Recruiting |
NCT05826080 -
Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism
|
||
Completed |
NCT04179019 -
Calcium Channel Blockade in Primary Aldosteronism
|
Phase 2 | |
Completed |
NCT03500120 -
Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism
|
||
Recruiting |
NCT04213963 -
Prospective Study on Primary Aldosteronism in Resistant Hypertension
|
||
Completed |
NCT05435703 -
Renal Cysts and Primary Aldosteronism
|
||
Recruiting |
NCT02945904 -
IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism
|
||
Enrolling by invitation |
NCT02257450 -
Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study
|
N/A | |
Recruiting |
NCT05561361 -
The Effect of SAAE on Vascular Endothelial Function in PA Patients
|
||
Completed |
NCT03398785 -
Adrenal Artery Ablation Treats Primary Aldosteronism
|
Phase 3 | |
Recruiting |
NCT04428827 -
Outcome of Patients With Primary Aldosteronism
|
||
Recruiting |
NCT03224312 -
Chongqing Primary Aldosteronism Study
|
||
Completed |
NCT02756754 -
Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism
|
N/A |